Compare CXE & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXE | STIM |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.6M | 140.6M |
| IPO Year | N/A | 2018 |
| Metric | CXE | STIM |
|---|---|---|
| Price | $3.75 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 69.8K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | N/A | $11.10 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | $53.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.40 | $0.80 |
| 52 Week High | $3.88 | $4.84 |
| Indicator | CXE | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 50.10 | 40.89 |
| Support Level | $3.65 | $1.23 |
| Resistance Level | $3.78 | $1.55 |
| Average True Range (ATR) | 0.04 | 0.22 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 56.25 | 4.49 |
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.